V
V. de Pril
Researcher at Bristol-Myers Squibb
Publications - 13
Citations - 832
V. de Pril is an academic researcher from Bristol-Myers Squibb. The author has contributed to research in topics: Ipilimumab & Nivolumab. The author has an hindex of 6, co-authored 13 publications receiving 772 citations.
Papers
More filters
Journal ArticleDOI
Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study
Steven J. O'Day,Michele Maio,Vanna Chiarion-Sileni,Thomas F. Gajewski,Hubert Pehamberger,Igor Bondarenko,Paola Queirolo,Lotta Lundgren,S. Mikhailov,Lynda D. Roman,Claire F. Verschraegen,R. Humphrey,Ramy Ibrahim,V. de Pril,Axel Hoos,Jedd D. Wolchok +15 more
TL;DR: Ipilimumab demonstrated clinical activity with encouraging long-term survival in a previously treated advanced melanoma population, and immune-related AEs were manageable and generally reversible with corticosteroids.
Journal ArticleDOI
Four-year survival rates for patients with metastatic melanoma who received ipilimumab in phase II clinical trials
Jedd D. Wolchok,Jeffrey S. Weber,Michele Maio,Bart Neyns,Kaan Harmankaya,Kevin M. Chin,L. Cykowski,V. de Pril,R. Humphrey,Céleste Lebbé +9 more
TL;DR: Durable survival in a significant proportion of patients with metastatic melanoma who received ipilimumab therapy is demonstrated, as well as ongoing survival follow-up, in a companion study.
Journal ArticleDOI
Adjuvant nivolumab (NIVO) versus ipilimumab (IPI) in resected stage III/IV melanoma: 3-year efficacy and biomarker results from the phase III CheckMate 238 trial
Jeffrey S. Weber,M. Del Vecchio,Mario Mandalà,Helen Gogas,Ana Arance,Stéphane Dalle,Charles Lance Cowey,Michael Schenker,J.-J. Grob,V. Chiarion-Sileni,Ivan Marquez-Rodas,Marcus O. Butler,Michele Maio,Mark R. Middleton,T. Tang,Abdel Saci,V. de Pril,Maurice Lobo,J.M.G. Larkin,P.A. Ascierto +19 more
Journal ArticleDOI
Association between immune-related adverse events (irAEs) and disease control or overall survival in patients (pts) with advanced melanoma treated with 10 mg/kg ipilimumab in three phase II clinical trials
Jose Lutzky,Jedd D. Wolchok,Omid Hamid,C. Lebbé,Hubert Pehamberger,Gerald P. Linette,V. de Pril,Ramy Ibrahim,Axel Hoos,Steven J. O'Day +9 more
TL;DR: DC and survival benefits with ipilimumab are observed among patients with advanced melanoma that develop an irAE and among pts that do not develop anirAE, and pts who do not experience an ir AE may still demonstrate clinical benefit with ipILimumab.
Journal ArticleDOI
melanoma and other skin tumoursIpilimumab (IPI) vs placebo (PBO) after complete resection of stage III melanoma: final overall survival results from the EORTC 18071 randomized, double-blind, phase 3 trial
Alexander M.M. Eggermont,V. Chiarion-Sileni,J.-J. Grob,Reinhard Dummer,Jedd D. Wolchok,Henrik Schmidt,Omid Hamid,C. Robert,P.A. Ascierto,Jon M. Richards,C. Lebbé,Virginia Ferraresi,Michael Smylie,Jeffrey S. Weber,Corina Taitt,V. de Pril,G. De Schaetzen,Stefan Suciu,Alessandro Testori +18 more